GlassScriptPhysician profile
Dana L Culpepper
NPI 1699083501
$6,544.47
in general payments reported to CMS, 2019-2025
23 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $1,366 · 2023: $1,738 · 2024: $1,546 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.03 |
| Education | $208.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,398.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $977.90 | 2021-2025 | |
| Janssen Biotech, INC. | $627.91 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $540.07 | 2021-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $464.25 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $440.56 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Incyte Corporation | $337.76 | 2021-2025 | Opzelura |
| Pfizer INC. | $284.94 | 2022-2025 | |
| Genzyme Corporation | $243.77 | 2022-2025 | |
| Leo Pharma INC. | $218.34 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $189.04 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $162.71 | 2023-2025 | Zoryve |
| Amgen INC. | $123.97 | 2021-2024 | Otezla |
| Genentech USA, INC. | $121.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.33 | 2022-2025 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $87.83 | 2022-2025 | Nemluvio |
| Dermavant Sciences, INC. | $61.10 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.89 | 2023-2025 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $33.22 | 2022-2023 | Valchlor |
| Fresenius Kabi USA, LLC | $30.32 | 2023-2024 | Idacio |
| Journey Medical Corporation | $20.09 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.25 | 2023 | Ycanth |
| Strata Skin Sciences, INC. | $14.02 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Culpepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.